These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23291951)

  • 21. Dendritic cell biology and its role in tumor immunotherapy.
    Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
    J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.
    Lahoud MH; Ahmet F; Kitsoulis S; Wan SS; Vremec D; Lee CN; Phipson B; Shi W; Smyth GK; Lew AM; Kato Y; Mueller SN; Davey GM; Heath WR; Shortman K; Caminschi I
    J Immunol; 2011 Jul; 187(2):842-50. PubMed ID: 21677141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.
    Yan Z; Wu Y; Du J; Li G; Wang S; Cao W; Zhou X; Wu C; Zhang D; Jing X; Li Y; Wang H; Gao Y; Qi Y
    Oncotarget; 2016 Jun; 7(26):40437-40450. PubMed ID: 27250027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
    Li J; Ahmet F; Sullivan LC; Brooks AG; Kent SJ; De Rose R; Salazar AM; Reis e Sousa C; Shortman K; Lahoud MH; Heath WR; Caminschi I
    Eur J Immunol; 2015 Mar; 45(3):854-64. PubMed ID: 25487143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of direct and cross-presentation to CTL immunity against herpes simplex virus 1.
    Jirmo AC; Nagel CH; Bohnen C; Sodeik B; Behrens GM
    J Immunol; 2009 Jan; 182(1):283-92. PubMed ID: 19109159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
    Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
    EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct and indirect T cell priming by dendritic cell vaccines.
    Cayeux S; Richter G; Becker C; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1999 Jan; 29(1):225-34. PubMed ID: 9933104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.
    Leleux J; Atalis A; Roy K
    J Control Release; 2015 Dec; 219():610-621. PubMed ID: 26489733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
    Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
    Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.
    Chen X; Liu Z; Huang Y; Li R; Zhang H; Dong S; Ge C; Zhang Z; Wang Y; Wang Y; Xue Y; Li Z; Song X
    Autoimmunity; 2014 Feb; 47(1):46-56. PubMed ID: 24191684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease.
    Kassianos AJ; Wang X; Sampangi S; Muczynski K; Healy H; Wilkinson R
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1391-401. PubMed ID: 24049150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
    Dullaers M; Thielemans K
    J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
    Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing dendritic cell-based approaches for cancer immunotherapy.
    Datta J; Terhune JH; Lowenfeld L; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Yale J Biol Med; 2014 Dec; 87(4):491-518. PubMed ID: 25506283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.
    Caminschi I; Vremec D; Ahmet F; Lahoud MH; Villadangos JA; Murphy KM; Heath WR; Shortman K
    Mol Immunol; 2012 Feb; 50(1-2):9-17. PubMed ID: 22209163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting dendritic cells for priming cellular immune responses.
    Gogolák P; Réthi B; Hajas G; Rajnavölgyi E
    J Mol Recognit; 2003; 16(5):299-317. PubMed ID: 14523943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.